Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (2315.HK)
| Previous close | 7.420 |
| Open | 7.420 |
| Bid | 7.350 x N/A |
| Ask | 7.400 x N/A |
| Day's range | 7.370 - 7.420 |
| 52-week range | 5.740 - 21.500 |
| Volume | |
| Avg. volume | 131,305 |
| Market cap | 2.956B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.030 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 17.69 |
PR NewswireBiocytogen Awarded U.S. Patent for RenLite® Common Light Chain Mouse Platform
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced United States Patent and Trademark Office (USPTO) patent grant for independently developed RenLite® fully human common light chain mouse platform.
Simply Wall St.SEHK Growth Companies With High Insider Ownership Showcasing Promising Futures
Amidst a landscape of fluctuating global markets, the Hong Kong stock market continues to present unique opportunities for discerning investors. This article explores three growth-oriented companies in the SEHK with high insider ownership, a trait often associated with strong confidence in a company's future prospects and alignment of interests between shareholders and management.
- Simply Wall St.
Exploring Three SEHK Growth Companies With High Insider Ownership
Amidst a backdrop of fluctuating global markets, Hong Kong's Hang Seng Index recently showcased a robust gain of 3.11%, signaling a positive sentiment in the region. This uptick provides an intriguing context for examining growth companies with high insider ownership on the SEHK, as such firms often benefit from aligned interests between shareholders and management, potentially enhancing stability and confidence in challenging economic climates.
